Perhaps not coincidentally, as the presented AD model suggests, HDAC2, whose elevated levels are commonly associated with neurodegenerative disorders, is an oncogene, whereas HDAC inhibitors are considered as a new promising class of anti-cancer drugs [114, 117]. This evidence concerns the gene HDAC9 and Alzheimer disease.